Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for QIAGEN N.V. (QGEN : NYSE)

• Company Description    QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia. Number of Employees: 5,765

• Price / Volume Information    Yesterday's Closing Price: $44.97 Daily Weekly Monthly 20 Day Moving Average: 998,936 shares Shares Outstanding: 222.29 (millions) Market Capitalization: $9,996.42 (millions) Beta: 0.66 52 Week High: $51.88 52 Week Low: $37.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.48% -4.32% 12 Week -4.18% -5.72% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL HULSTERWEG 82 - PL VENLO,P7 5912 NLD ph: 31-77-355-6600 fax: 31-77-355-6658 john.gilardi@qiagen.com http://www.qiagen.com

• General Corporate Information    Officers Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Toralf Haag - Supervisory Director Eva Pisa - Supervisory Director Metin Colpan - Supervisory Director Peer Information QIAGEN N.V. (CORR.) QIAGEN N.V. (RSPI) QIAGEN N.V. (CGXP) QIAGEN N.V. (BGEN) QIAGEN N.V. (GTBP) QIAGEN N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N72482206 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/04/26 Share - Related Items Shares Outstanding: 222.29 Most Recent Split Date: 1.00 (0.97:1) Beta: 0.66 Market Capitalization: $9,996.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.56% Current Fiscal Quarter EPS Consensus Estimate: $0.58 Indicated Annual Dividend: $0.25 Current Fiscal Year EPS Consensus Estimate: $2.48 Payout Ratio: 0.11 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.10 Estmated Long-Term EPS Growth Rate: 8.31% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/04/26

• Fundamental Ratios P/E Current FY Estimate: 18.10 Trailing 12 Months: 18.98 PEG Ratio: 2.18 Price Ratios Price/Book: 2.74 Price/Cash Flow: 14.03 Price / Sales: 4.83 EPS Growth vs. Year Ago Period: 4.04% vs. Previous Quarter: 1.67% Sales Growth vs. Year Ago Period: 6.12% vs. Previous Quarter: -0.18% ROE 12/31/25 - - 09/30/25 - 14.80 06/30/25 - 14.77 ROA 12/31/25 - - 09/30/25 - 8.86 06/30/25 - 8.87 Current Ratio 12/31/25 - - 09/30/25 - 2.60 06/30/25 - 1.61 Quick Ratio 12/31/25 - - 09/30/25 - 2.30 06/30/25 - 1.35 Operating Margin 12/31/25 - - 09/30/25 - 25.25 06/30/25 - 25.35 Net Margin 12/31/25 - - 09/30/25 - 19.58 06/30/25 - 18.30 Pre-Tax Margin 12/31/25 - - 09/30/25 - 24.48 06/30/25 - 23.95 Book Value 12/31/25 - - 09/30/25 - 16.42 06/30/25 - 15.77 Inventory Turnover 12/31/25 - - 09/30/25 - 2.67 06/30/25 - 2.57 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.45 06/30/25 - 0.25 Debt-to-Capital 12/31/25 - - 09/30/25 - 30.84 06/30/25 - 20.15

Powered by Zacks Investment Research ©